USACSCI
COSCIENS Biopharma sets July 3 effective date for share capital amendment
COSCIENS Biopharma announced that its share capital amendment, approved by shareholders on June 17, 2026, will become effective on July 3, 2026. The amendment consists of a 1-for-150 consolidation of common shares followed immediately by a 50-for-1 split, resulting in a net reduction of pre-consolidation holdings by a factor of three for shareholders holding 150 or more common shares. Shareholders with fewer than 150 common shares as of the effective date will instead receive cash consideration of US$1.60 per pre-consolidation share. The common shares are expected to begin trading on the Toronto Stock Exchange on a post-amendment basis within two business days of the effective date under the same symbol CSCI. The company also plans to file a Form 15 with the U.S. Securities and Exchange Commission to suspend its U.S. reporting obligations.